KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Safety, Growth, and Development After Dapagliflozin or Saxagliptin in Children With Type 2 Diabetes (T2NOW Follow-Up). PMID 39446459 · J Clin Endocrinol Metab · 2025-May-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1. PMID 39378125 · J Clin Endocrinol Metab · 2025-May-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12. PMID 39243386 · J Clin Endocrinol Metab · 2025-May-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Diverse Lenabasum pathway activation in dermatomyositis patients' blood. PMID 40383862 · Sci Rep · 2025-May-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
State-of-the-Art Evidence for Clinical Outcomes and Therapeutic Implications of Janus Kinase Inhibitors in Moderate-to-Severe Ulcerative Colitis: A Narrative Review. PMID 40430558 · Pharmaceuticals (Basel) · 2025-May-17 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Primary prevention of cardiotoxicity in cancer patients treated with fluoropyrimidines: a randomized controlled trial. PMID 40382663 · Cardiooncology · 2025-May-17 The record describes a randomized trial in cancer patients with a drug intervention (fluoropyrimidines) and a primary time-to-event endpoint (composite including all-cause mortality, analyzed via Kaplan-Meier). However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the abstract or metadata; it appears to be a Phase II or earlier trial based on its single-center design, sample size, and focus on prevention rather than definitive efficacy comparison.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. PMID 40347969 · Lancet · 2025-May-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Induction of labour versus standard care to prevent shoulder dystocia in fetuses suspected to be large for gestational age in the UK (the Big Baby trial): a multicentre, open-label, randomised controlled trial. PMID 40319899 · Lancet · 2025-May-17 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
DeintensiF: Standard versus individualized deintensified follow-up after curative treatment in head and neck cancer: protocol of a randomized pilot study. PMID 40380278 · Pilot Feasibility Stud · 2025-May-16 The record is a protocol for a randomized pilot study comparing follow-up strategies (not a drug intervention) in head and neck cancer. It is not a Phase III/IIIb trial, does not report results, and lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A CT-based intratumoral and peritumoral radiomics nomogram for postoperative recurrence risk stratification in localized clear cell renal cell carcinoma. PMID 40380110 · BMC Med Imaging · 2025-May-16 The study is an oncology, human, randomized study with time-to-event endpoints, but it is a diagnostic/prognostic model development and validation study, not a randomized trial of a drug-containing intervention. It lacks a drug intervention arm and does not test the efficacy of a therapeutic agent.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
SLE-DAS enables an accurate definition of severe lupus disease activity: derivation and validation in a post hoc study of anifrolumab phase II and III studies. PMID 40379439 · Lupus Sci Med · 2025-May-16 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring. PMID 40375301 · Mol Cancer · 2025-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effects of metformin on transcriptomic and metabolomic profiles in breast cancer survivors enrolled in the randomized placebo-controlled MetBreCS trial. PMID 40374694 · Sci Rep · 2025-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Second-Line Antiretroviral Therapy for Children Living with HIV in Africa. PMID 40367375 · N Engl J Med · 2025-May-15 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum-based treatment: A phase 1/2 trial. PMID 40366884 · Cancer · 2025-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non-small cell lung cancer with programmed cell death-ligand 1 ≥50. PMID 40323717 · Cancer · 2025-May-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial. PMID 40293268 · Clin Cancer Res · 2025-May-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis. PMID 40202696 · N Engl J Med · 2025-May-15 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis. PMID 40202623 · N Engl J Med · 2025-May-15 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Randomized, Double-Blind, Placebo-Controlled, Multicentered Study to Evaluate the Efficacy and Safety of MEI005 in Reducing Submental Fat in Chinese Adults. PMID 40037621 · Aesthet Surg J · 2025-May-15 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
PERK+ Macrophages Drive Immunotherapy Resistance in Lymph Node Metastases of Oral Squamous Cell Carcinoma. PMID 40036693 · Clin Cancer Res · 2025-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Phase 2 trial of veliparib, local irradiation, and temozolomide in patients with newly diagnosed high-grade glioma: a Children's Oncology Group study. PMID 39560182 · Neuro Oncol · 2025-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Advancing human-use experience for real-world evidence for the registration of traditional Chinese medicine products in China. PMID 40369511 · BMC Complement Med Ther · 2025-May-14 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: long-term results of a randomized controlled trial. PMID 40369294 · Int J Colorectal Dis · 2025-May-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge study. PMID 40367195 · Sci Transl Med · 2025-May-14 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Electromechanical-assisted training for walking after stroke. PMID 40365867 · Cochrane Database Syst Rev · 2025-May-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Tuberculosis disease characteristics associated with mortality, severe morbidity and unsuccessful treatment in people living with HIV treated for tuberculosis - a secondary analysis of the ANRS 12300 Reflate TB2 trial. PMID 40361016 · BMC Infect Dis · 2025-May-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Partial Breast Reirradiation for Breast Cancer Recurrences After Repeat Breast-Conserving Surgery with Proton Beam Therapy: The Prospective BREAST Trial (NCT06954623). PMID 40429411 · J Clin Med · 2025-May-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Microbiome-directed food to promote sustained recovery in children with uncomplicated acute malnutrition: protocol for a randomized controlled trial in Burkina Faso. PMID 40361242 · BMC Nutr · 2025-May-13 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study. PMID 40245351 · Neurology · 2025-May-13 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Inhaled Sedation in Acute Respiratory Distress Syndrome: The SESAR Randomized Clinical Trial. PMID 40098564 · JAMA · 2025-May-13 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma. PMID 40030008 · Blood Adv · 2025-May-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma. PMID 39951620 · Blood Adv · 2025-May-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia. PMID 39928953 · Blood Adv · 2025-May-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review. PMID 39825862 · Blood Adv · 2025-May-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Wearable Devices in Remote Cardiac Rehabilitation With and Without Weekly Online Coaching for Patients With Coronary Artery Disease: Randomized Controlled Trial. PMID 40395066 · JMIR Mhealth Uhealth · 2025-May-12 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Probiotic reduces vaginal HPV abundance, improves immunity and quality of life in HPV-positive women: a randomised, placebo-controlled and double-blind study. PMID 40360161 · Benef Microbes · 2025-May-12 The study is randomized and phase-definitive but lacks a drug intervention and a time-to-event efficacy endpoint. It is a probiotic trial for HPV infection, not a cancer treatment trial.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effectiveness of a community-based rehabilitation programme following hip fracture: results from the Fracture in the Elderly Multidisciplinary Rehabilitation phase III (FEMuR III) randomised controlled trial. PMID 40355296 · BMJ Open · 2025-May-12 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial. PMID 40350430 · Breast Cancer Res · 2025-May-12 This is a randomized window-of-opportunity trial assessing biological effects (TILs, proliferation, apoptosis) of denosumab in early breast cancer, not a Phase II/III or III trial with a primary or key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Corticosteroid Use in Randomized Clinical Trials of Biologics and Small Molecules in Inflammatory Bowel Disease: A Systematic Review. PMID 39419764 · Inflamm Bowel Dis · 2025-May-12 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study. PMID 40350200 · RMD Open · 2025-May-11 The record describes a Phase III randomized trial of a drug (upadacitinib) for rheumatoid arthritis, which is not an oncology condition. No time-to-event efficacy endpoints are reported.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Juntas Contra el Virus del Papiloma Humano: protocol for a pilot randomized controlled trial of an HPV self-sampling intervention for underscreened Latinas. PMID 40349085 · Pilot Feasibility Stud · 2025-May-10 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial. PMID 40252681 · Lancet · 2025-May-10 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot to lot consistency of single component oral cholera vaccine BBV131 (Hillchol®) in comparison to Shanchol™. PMID 40174256 · Vaccine · 2025-May-10 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study. PMID 40036726 · J Clin Oncol · 2025-May-10 The record describes a biomarker analysis (clonal/subclonal mutations) within a Phase III neuroblastoma trial. While it meets criteria for oncology, human, randomized trial, Phase III, and time-to-event endpoints, it does not include a drug-containing intervention as the subject of analysis. The study is a prognostic analysis, not the primary report of the trial's drug intervention efficacy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effects of saffron supplementation on inflammation and hematological parameters in patients with sepsis: a randomized controlled trial. PMID 40346613 · Nutr J · 2025-May-09 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Primary percutaneous stenting above the ampulla versus endoscopic drainage for unresectable malignant hilar biliary obstruction (TESLA RCT): study protocol for a multicenter randomized controlled trial. PMID 40346549 · BMC Cancer · 2025-May-09 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Thoracoscopy-guided thoracic paravertebral block using dexmedetomidine in combination with ropivacaine for postoperative analgesia after thoracoscopic radical resection of lung cancer: a randomized controlled trial. PMID 40343511 · J Cancer Res Clin Oncol · 2025-May-09 While the study is a randomized trial of a drug intervention in an oncology population, it is excluded because it does not meet the required time-to-event efficacy endpoint for a cancer trial (the primary endpoint is an analgesia measure) and the trial phase is not confirmed as definitive (Phase III/IIIb or Phase II/III).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial. PMID 39827881 · Med · 2025-May-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study. PMID 39740666 · Med · 2025-May-09 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -